Aktovegin tab n / 200mg about 50 pc

Description

Composition
Active substance:
1 tablet contains: Blood Components: Blood gemoderivat deproteinised calves – 200.0 mg of granulate Aktovegin® * – 345.0 mg
* Aktovegin® granulate contains: active substance: Blood Components: Blood gemoderivat deproteinised calves – 200.0 mg excipients: Povidone K-90 – 10.0 mg Microcrystalline cellulose – 135.0 mg.
Excipients:
Magnesium stearate – 2.0 mg Talc – 3.0 mg; Sheath: acacia gum – 6.8 mg, mountain wax glycol – 0.1 mg hypromellose phthalate – 29.45 mg, diethylphthalate – 11.8 mg, quinoline yellow dye lacquer aluminum – 2.0 mg macrogol 6000 – 2 95 mg povidone K-30 – 1.54 mg sucrose – 52.3 mg talc – 42.2 mg titanium dioxide – 0.86 mg.
Description:
Round biconvex film-coated tablets, greenish-yellow, shiny.
Product form:
Tablets 200 mg film-coated. 50 tablets in dark glass bottles with a screw neck, sealed with aluminum caps with the first control opening. 1 vial with instructions for use placed in a pile of cardboard. A pack of transparent protective paste stickers round shape with holographic labels and tamper-evident.
In the case of production and / or packaging and the packaging of the drug in the LLC “Takeda Pharmaceuticals”, Russia: 50 tablets in bottles of dark glass with screw neck, sealed with aluminum caps with tamper-evident. 1 vial with instructions for use placed in a pile of cardboard. A pack of transparent protective paste stickers round shape with holographic labels and tamper-evident.
In the case of packaging and packing of the drug on the JSC “PharmFirma” Sotex “Russia: On 10, 30 or 50 tablets in bottles of dark glass with screw neck, sealed with aluminum caps with tamper-evident. 1 vial with instructions for use placed in a pile of cardboard.
Contraindications
Aktovegin® hypersensitivity to the drug or drugs and the same excipients. • fructose intolerance, glucose-galactose malabsorption or saharazo- izomaltaznaya failure. • Children up to age 18 years
Carefully
Pregnancy and breast-feeding.
Indications
In the combined treatments: • Symptomatic treatment of cognitive disorders, including post stroke cognitive impairment and dementia. • Symptomatic treatment of peripheral circulatory disorders and their consequences. • Symptomatic treatment of diabetic polyneuropathy (DPN).
Interaction with other drugs
It is currently unknown.
Overdose
According to preclinical studies Aktovegin® shows no toxic effects, even at doses in excess of 30-40 times compared to the doses recommended for use in humans. There were no cases of drug overdose Aktovegin®.
pharmachologic effect
Pharmacological group:
Tissue regeneration stimulator.
Pharmacodynamics:
Aktovegin – antihypoxant, providing three types of effects: metabolic, neuroprotective and microcirculation. Aktovegin improves uptake and oxygen utilization; included in the formulation inositol phospho-oligosaccharides positively influence the transport and utilization of glucose, which leads to an improvement in the energy metabolism of cells and reduction of lactate formation in ischemic conditions. We consider several ways to implement the neuroprotective mechanism of action of the drug. Aktovegin prevents the development of apoptosis induced by amyloid-beta peptide (Abeta25-35). Aktovegin modulates the activity of nuclear factor kappa B (NF-kB), which plays an important role in the regulation of apoptosis and inflammation in the central and peripheral nervous system. Another mechanism of action is associated with the nuclear enzyme poly (ADP-ribose) polymerase (PARP). PARP plays a role in repair of damage detection and single-stranded DNA, however, excessive activation of the enzyme can trigger cell death processes in conditions such as cerebrovascular disease and diabetic neuropathy. Aktovegin inhibits PARP activity, which leads to improvement of morphological and functional state of the central and peripheral nervous system. Positive effects of the drug Aktovegin influencing the microcirculation and on endothelium, are increased capillary blood flow, reduction pericapillary zone decrease myogenic tone precapillary arterioles and capillary sphincters, the reduction degree arteriolovenulyarnogo shunt blood flow with a predominant circulating blood in the capillary bed and stimulation of the function of endothelial synthase oxide nitrogen affecting the microvasculature. In various studies it was found that the effect of the drug Aktovegin occurs not later than 30 minutes after administration. The maximum effect is observed after 3 hours after parenteral and 2-6 hours after oral administration.
Pharmacokinetics:
Using methods impossible pharmacokinetic study Aktovegin® pharmacokinetic parameters of the drug because it consists only of physiological components which are normally present in the body.
Pregnancy and breast-feeding
Aktovegin® should be used only in cases where the therapeutic benefit outweighs the potential risk to the fetus or child.
Conditions of supply of pharmacies
Prescription.
side effects
The frequency of side effects was determined in accordance with the classification of the Council for International Organizations of Medical Sciences (CIOMS): very common (> 1/10); often ((> 1/100 to
special instructions
Clinical data In a multicenter, randomized, double-blind, placebo-controlled ARTEMIDA (NCT01582854) study whose purpose was to study the therapeutic effect of the drug Aktovegin® against cognitive disorders in 503 patients with stroke, the overall incidence of serious adverse events and death was similar in both treatment groups. Although the incidence of recurrent ischemic stroke was within the expected in this population of patients was recorded by a greater number of cases in the group treated with the drug Aktovegin®, compared with the placebo group, but this difference was not statistically significant. Interrelationships between cases and recurrent stroke study medication has not been established.
Use in pediatric patients Currently, data on the use of the drug in pediatric Aktovegin® persons are absent, therefore its use in this group of persons is not recommended.
Effect on driving ability and other mechanisms
Not installed.
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children!.
Dosing and Administration
Inside, not liquid, the food, squeezed small amounts of liquid.
Post stroke cognitive impairment
In the acute phase of ischemic stroke, starting from 5 – 7 day and 2000 mg a day intravenously to 20 infusions transition to tablet form 2 tablets 3 times a day (1200 mg / day). The total duration of treatment of 6 months
dementia
2 tablets 3 times a day (1200 mg / day). The total duration of treatment of 20 weeks. Peripheral circulatory disorders and their consequences 1-2 tablets three times a day (600 – 1200 mg / day). The duration of treatment of 4 to 6 weeks
diabetic polyneuropathy
To 2000 mg per day intravenously 20 infusions transition to tablet form 3 tablets 3 times a day (1800 mg / day) Duration of 4 to 5 months.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist